Unknown

Dataset Information

0

The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis.


ABSTRACT:

Background

Hypoxia-induced angiogenesis functions importantly in anaplastic thyroid cancer (ATC) progression. However, the therapeutic potential of broad-spectrum anti-angiogenic agent remains undefined. Anlotinib conventionally targets VEGFR, FGFR and PDGFR. Here, a novel role of anlotinib on ATC angiogenesis was illustrated.

Methods

Molecular expressions were established via tissue microarray. Multiple assays (tubule formation, 3D sprouting and chicken chorioallantoic membrane model) were used for angiogenic evaluation. Panels of molecular screening were achieved by antibody and PCR arrays. The loop binding motif of EGFR for homology modelling was prepared using Maestro.

Results

Anlotinib could dose- and time-dependently inhibit cell viability under normoxia and hypoxia and could repress hypoxia-activated angiogenesis more efficiently in vitro and in vivo. CXCL11 and phospho-EGFR were hypoxia-upregulated with a positive correlation. The cancer-endothelium crosstalk could be mediated by the positive CXCL11-EGF-EGFR feedback loop, which could be blocked by anlotinib directly targeting EGFR via a dual mechanism by simultaneous inhibitory effects on cancer and endothelial cells. The AKT-mTOR pathway was involved in this regulatory network.

Conclusions

The newly identified CXCL11-EGF-EGFR signalling provided mechanistic insight into the interaction between cancer and endothelial cells under hypoxia, and EGFR was a novel target. Anlotinib may be the encouraging therapeutic candidate in ATC.

SUBMITTER: Liang J 

PROVIDER: S-EPMC8328993 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis.

Liang Juyong J   Jin Zhijian Z   Kuang Jie J   Feng Haoran H   Zhao Qiwu Q   Yang Zheyu Z   Zhan Ling L   Shen Baiyong B   Yan Jiqi J   Cai Wei W   Cheng Xi X   Qiu Weihua W  

British journal of cancer 20210604 3


<h4>Background</h4>Hypoxia-induced angiogenesis functions importantly in anaplastic thyroid cancer (ATC) progression. However, the therapeutic potential of broad-spectrum anti-angiogenic agent remains undefined. Anlotinib conventionally targets VEGFR, FGFR and PDGFR. Here, a novel role of anlotinib on ATC angiogenesis was illustrated.<h4>Methods</h4>Molecular expressions were established via tissue microarray. Multiple assays (tubule formation, 3D sprouting and chicken chorioallantoic membrane m  ...[more]

Similar Datasets

| S-EPMC10448565 | biostudies-literature
| S-EPMC5802699 | biostudies-literature
| S-EPMC3930409 | biostudies-literature
| S-EPMC7017291 | biostudies-literature
| S-EPMC6368736 | biostudies-literature
| S-EPMC3969863 | biostudies-literature
| S-EPMC10516035 | biostudies-literature
| S-EPMC3041948 | biostudies-literature
| S-EPMC6391393 | biostudies-literature
| S-EPMC2865566 | biostudies-literature